Menopausal Hormone Therapy
Oestrogen ± progestogen for menopausal symptoms (MHT/HRT)
For symptomatic women under 60 or within 10 years of menopause, and without contraindications, hormone therapy is the most effective treatment for vasomotor symptoms and the benefits generally outweigh the risks. It is not recommended for chronic disease prevention. Timing, route, and formulation materially change the risk profile.
How confident is BioSignal?
Our overall position, and how sure we are of it across each dimension — including where we are not sure at all.
High confidence
For symptomatic women under 60 or within 10 years of menopause, and without contraindications, hormone therapy is the most effective treatment for vasomotor symptoms and the benefits generally outweigh the risks. It is not recommended for chronic disease prevention. Timing, route, and formulation materially change the risk profile.
Well-supported by consistent, high-quality evidence.
Biological Role
The symptoms of menopause are caused by oestrogen decline. Replacing oestrogen treats the cause, not merely the symptom — which is why it works so much better than the alternatives.
Human Evidence
Extensive randomised evidence, including the Women's Health Initiative and decades of subsequent reanalysis that established the timing hypothesis.
Benefit For Symptoms
The most effective treatment available for vasomotor symptoms. Nothing else comes close.
Broader Claims
It is not recommended as a therapy to prevent cardiovascular disease or dementia. Bone protection is real but is a secondary consideration for most women.
Safety Confidence
Risks are real but modest in absolute terms, and depend heavily on age at initiation, time since menopause, route, and whether a progestogen is required.
Research Activity
Active work on individualised risk prediction, newer non-hormonal options, and undoing two decades of clinical misunderstanding.
Where the evidence stands today
How mature the science is, what kinds of evidence exist, and — the part nobody else prints — what is still missing.
9/9
steps proven in humans
Evidence-rich
Proven at every applicable step — rare, and worth noticing.
Guideline / regulatory support
ProvenFirst-line for vasomotor symptoms in appropriate candidates.
Clinical outcomes
ProvenSymptom relief and fracture reduction demonstrated.
Large human RCTs
ProvenThe Women's Health Initiative and others.
Small human outcome trials
ProvenNumerous symptom trials.
Human safety data
ProvenExtensive, including long-term follow-up.
Human biomarker / pharmacology
ProvenReliable symptom and bone-density effects.
Animal
ProvenExtensive.
Cell / in vitro
ProvenOestrogen receptor biology well characterised.
Mechanistic plausibility
ProvenSymptoms are caused by oestrogen decline.
The bottom line
What we know, what we think, what we don't know — and what would change our mind.
What We Know
Hormone therapy is the most effective treatment for hot flushes and night sweats, and it prevents the accelerated bone loss that follows menopause. These are not marginal effects.
What We Think
Timing is the decisive variable. For women under 60 or within 10 years of menopause, without contraindications, the benefit-to-risk balance is favourable and the absolute risks are small.
What We Don't Know
How to predict individual risk precisely, the optimal duration of therapy, and how far the reassuring findings for newer formulations and routes extend.
Active Research
Individualised risk stratification, non-hormonal alternatives such as NK3-receptor antagonists, and long-term outcomes with transdermal routes and micronised progesterone.
What Could Change Our Mind
Long-term outcome data on newer formulations, and any finding that shifts the breast-cancer risk estimates materially in either direction.
The biggest myth
“The Women's Health Initiative showed hormone therapy is dangerous”
The trial's findings were widely over-generalised. Its participants were on average well past menopause, and the risks reported do not transfer to the younger, recently menopausal women who most want treatment. Subsequent reanalysis established that timing changes the picture substantially.
Ask BioSignal
Still have a question about menopausal hormone therapy?
Answers are retrieved from this record and the rest of the knowledge graph — never generated.
Why people take menopausal hormone therapy
Popularity is not evidence — but it is not stupid either. This explains the interest on its own terms.
Menopausal hormone therapy is the rare case where BioSignal's job is to say a treatment is BETTER than its reputation. A misread trial collapsed its use, and millions of women were left to endure symptoms that had an effective treatment. Correcting an overstated risk is the same discipline as deflating an overstated benefit.
If you're here because…
Jump straight to the part of the evidence that answers your question.
Approval, safety and regulatory
What it is approved for, who should be careful, what remains unknown — and the limits of what this evidence can tell you.
Regulatory status
FDA-approved for moderate-to-severe vasomotor symptoms of menopause and for prevention of postmenopausal osteoporosis
Availability
Prescription only
Sport (WADA)
Not a prohibited class for this indication (confirm at publication)
Known safety profile
Risks are real but modest in absolute terms, and they depend heavily on age at initiation, time since menopause, route of administration, and whether a progestogen is required. Blanket statements in either direction are wrong.
Common issues
- Breast tenderness
- Irregular bleeding, particularly in the early months
- Bloating and mood changes
- Headache
Use caution if
- Women with a history of breast cancer
- Women with a history of venous thromboembolism or stroke
- Women with active liver disease
- Women with unexplained vaginal bleeding (must be investigated first)
- Women with coronary heart disease (individualised assessment)
Long-term unknowns
Long-term outcomes with newer body-identical formulations and transdermal routes are less fully characterised than for the older oral preparations studied in the landmark trials.
Limits of this evidence
The landmark trial population was, on average, well past menopause and older than the women who most want treatment — which is precisely why its risk estimates were misapplied. The honest limitation runs in the unusual direction here: the risks of this therapy have been overstated in the public mind, not understated.
Full regulatory and sport detail
- Regulatory approval
- Approved for moderate-to-severe vasomotor symptoms of menopause, for genitourinary symptoms, and for prevention of postmenopausal osteoporosis.
- Approved indication
- Vasomotor symptoms; genitourinary syndrome of menopause; osteoporosis prevention.
- Research chemical
- N/A — a licensed medicine. Compounded 'bioidentical' preparations sit outside this regulatory framework and are not recommended.
- Sport (WADA)
- Not a prohibited class for this indication — confirm against the current list.
- Publication note
- Re-confirm regulatory status against primary sources at publication.
Demand, separated from evidence
Every claim people make about this, counted against what the evidence actually showed.
BioSignal evaluated 9 popular claims about menopausal hormone therapy.
Here is where each one landed — including the claims of harm, where “not established” is reassuring rather than damning.
- Supported by evidence
- 3
- Mixed evidence
- 1
- Not established
- 5
Popularity is not evidence. This is simply a count of every claim BioSignal evaluated on this page, sorted by what the evidence actually showed — the full reasoning behind each verdict is in the Evidence Review below.
Supported by evidence
- Hormone therapy is the most effective treatment for hot flushes and night sweats
- Hormone therapy prevents bone loss and fractures
- Hormone therapy increases the risk of blood clots
Mixed evidence
- Hormone therapy causes breast cancer
Not established
- The Women's Health Initiative showed hormone therapy is dangerous
- Vaginal oestrogen carries the same risks as systemic hormone therapy
- Hormone therapy should be taken to prevent heart disease or dementia
- Women must stop hormone therapy after five years
- 'Bioidentical' compounded hormones are safer than regulated hormone therapy
The evidence review
Every claim with the reasoning behind its verdict, the doses actually studied, where scientists agree and disagree, and the questions still open.
What people claim
Every popular claim, with BioSignal’s verdict and how confident we are in it. The verdicts are always visible; open any claim to read the evidence behind it.
Hormone therapy is the most effective treatment for hot flushes and night sweatsSupportedHigh confidence
Consistently and substantially more effective than any alternative for vasomotor symptoms. This is its core, well-established indication.
Hormone therapy prevents bone loss and fracturesSupportedHigh confidence
Oestrogen prevents the accelerated bone loss that follows menopause and reduces fracture risk — a genuine benefit, though not on its own the usual reason to start.
Hormone therapy causes breast cancerMixedModerate confidence
This requires precision. Combined oestrogen–progestogen therapy is associated with a small increase in breast cancer risk that grows with duration of use. But in the WHI's oestrogen-only arm — women who had had a hysterectomy — breast cancer incidence was NOT increased. Stating 'HRT causes breast cancer' without that distinction is inaccurate and has caused real harm.
Hormone therapy increases the risk of blood clotsSupportedModerate confidence
Oral oestrogen increases venous thromboembolism risk. Transdermal oestrogen — patches and gels — carries a lower risk, which is why route of administration is a genuine clinical decision rather than a preference.
Vaginal oestrogen carries the same risks as systemic hormone therapyNot establishedModerate confidence
It does not. Low-dose vaginal oestrogen for genitourinary symptoms produces minimal systemic absorption. Fear generalised from systemic therapy leads many women to endure treatable symptoms unnecessarily.
Hormone therapy should be taken to prevent heart disease or dementiaNot establishedModerate confidence
It is not recommended for chronic disease prevention. This is an important limit: the case for hormone therapy rests on treating symptoms and protecting bone, not on preventing future disease.
Women must stop hormone therapy after five yearsNot establishedModerate confidence
There is no arbitrary stop date. Duration should be individualised through periodic review of ongoing benefit and risk, not dictated by a rule of thumb.
'Bioidentical' compounded hormones are safer than regulated hormone therapyNot establishedModerate confidence
Compounded 'bioidentical' preparations are not subject to the same regulatory oversight, have unverified dosing and purity, and are not supported by evidence of superior safety. Regulated body-identical hormones exist and are the appropriate option.
Doses used in human studies
What was actually given to participants in the research. These are descriptions of studies, not recommendations.
Women with a uterus, symptomatic
- Intervention
- Oestrogen plus a progestogen
- Dose
- Clinician-directed; lowest effective dose
- Duration
- Individualised, with periodic review
- Outcome
- Vasomotor symptom relief
- Notes
- The progestogen is required to protect the endometrium — it is not optional
Women after hysterectomy, symptomatic
- Intervention
- Oestrogen alone
- Dose
- Clinician-directed
- Duration
- Individualised, with periodic review
- Outcome
- Vasomotor symptom relief
- Notes
- No progestogen needed. In the WHI, this arm showed no increase in breast cancer
Women at higher clot risk
- Intervention
- Transdermal oestrogen (patch or gel)
- Dose
- Clinician-directed
- Duration
- Individualised
- Outcome
- Symptom relief with lower VTE risk
- Notes
- Transdermal avoids first-pass liver metabolism and carries lower thromboembolic risk than oral
Women with genitourinary symptoms only
- Intervention
- Low-dose vaginal oestrogen
- Dose
- Clinician-directed, low dose
- Duration
- Often long-term
- Outcome
- Vaginal dryness, discomfort, urinary symptoms
- Notes
- Minimal systemic absorption; the systemic risk profile does not apply
Where scientists agree — and don’t
Agreed
- Hormone therapy is the most effective treatment for vasomotor symptoms.
- For women under 60 or within 10 years of menopause, benefits generally outweigh risks.
- A progestogen is required to protect the endometrium in women with a uterus.
- Transdermal oestrogen carries lower thromboembolic risk than oral.
- Low-dose vaginal oestrogen has minimal systemic absorption.
- It is not indicated for chronic disease prevention.
Debated
- The precise magnitude of breast-cancer risk with different progestogens.
- Optimal duration of therapy, and how to stop.
- How far the timing hypothesis can be pushed in older women with persistent symptoms.
Unknown
- How to predict individual risk with precision.
- Long-term outcomes with newer body-identical formulations.
- Whether earlier initiation confers any lasting cardiovascular benefit.
What remains unknown
- Can individual breast-cancer and cardiovascular risk be predicted well enough to personalise therapy?
- Do micronised progesterone and newer progestogens carry lower breast-cancer risk than older ones?
- What is the optimal duration, and what is the best way to stop?
- How should women with premature menopause — a different situation entirely — be treated long-term?
Questions people actually ask
What is menopausal hormone therapy?
It is replacement of the oestrogen the ovaries stop producing at menopause, with a progestogen added for women who still have a uterus in order to protect the lining of the womb. It treats the cause of menopausal symptoms rather than working around them, which is why it is so much more effective than the alternatives.
Didn't a big study show HRT causes breast cancer?
That is the version that reached the headlines in 2002, and it was a misreading with serious consequences. The detail matters: in the arm of that trial where women who had had a hysterectomy took oestrogen alone, breast cancer was not increased. The increased risk was seen with combined oestrogen–progestogen therapy, it grew with duration of use, and in absolute terms it was small. Two decades of women went untreated for debilitating symptoms because that nuance was lost.
Am I too old to start hormone therapy?
Timing is the key variable. For women under 60, or within 10 years of menopause, and without contraindications, the balance of benefit and risk is generally favourable. Starting much later shifts that balance, which is why the conversation is different at 52 than at 68. It is a discussion to have with a clinician rather than a rule to apply.
I only have vaginal dryness. Do I need systemic hormones?
Probably not. Low-dose vaginal oestrogen treats genitourinary symptoms very effectively with minimal absorption into the bloodstream, so the risks associated with systemic therapy largely do not apply. Many women endure these symptoms for years out of a fear that, in this specific case, is misplaced.
What if I can't take hormones?
There are genuinely useful non-hormonal options: NK3-receptor antagonists such as fezolinetant, certain SSRIs and SNRIs, gabapentin, and cognitive behavioural therapy. They are less effective than hormone therapy for hot flushes, but they are real treatments — not consolation prizes.
Practical takeaways
- Hormone therapy is the most effective treatment for hot flushes and night sweats. Nothing else is close.
- For most women under 60, or within 10 years of menopause, benefits outweigh risks — and the absolute risks are small.
- The 2002 headlines were misread, and two decades of under-treatment followed. That was a real harm.
- Details matter: oestrogen alone (after hysterectomy) did not increase breast cancer; transdermal routes lower clot risk.
- Vaginal oestrogen for genitourinary symptoms is highly effective and carries minimal systemic risk — many women avoid it for no good reason.
How it works
The mechanism comes last on purpose. A compelling explanation of how something might work is the easiest part of the story to tell, and the part most likely to outlive the evidence for it.
The symptoms of menopause are caused by oestrogen decline. Replacing oestrogen treats the cause, not merely the symptom — which is why it works so much better than the alternatives.
How we found out
Widespread Use
Hormone therapy was widely prescribed, including — on the basis of observational data — for the prevention of chronic disease, an indication that was never properly established.
The WHI and the Collapse
The Women's Health Initiative reported in 2002. Its findings were communicated and received in a way that caused hormone therapy use to collapse worldwide, and women were left untreated for debilitating symptoms.
Reanalysis and the Timing Hypothesis
Subsequent analysis established that age at initiation and time since menopause change the risk-benefit balance substantially, and that the oestrogen-only arm had not shown an increase in breast cancer.
Rehabilitation and New Options
Guidelines re-established hormone therapy as first-line for vasomotor symptoms in appropriate candidates, alongside the arrival of genuinely effective non-hormonal alternatives such as NK3-receptor antagonists.
References
Verified sources. BioSignal does not print a citation it has not checked.
References for this record are being verified and will be published with the next review. BioSignal does not print citations it has not checked.
Version history
Version 1.0
Initial record for the Hormonal Health Ecosystem, authored to the Creatine benchmark. Calibration: Established maturity, HIGH confidence — an uncommon direction for BioSignal, and the correct one. Here the public perception overstates the risk, and anti-hype means correcting that too. Review cadence: Annually.
Continue exploring
Three places this record leads next.